TScan Therapeutics Announces Upcoming Trial In Progress Poster Presentation At The 2023 American Society Of Clinical Oncology Annual Meeting On June 3, 2023; 8:00 am – 11:00 am CDT

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will be presenting a Trial in Progress (TIP) poster at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held from June 2-6, 2023, at McCormick Place in Chicago, Illinois and online.

Presentation Details:

Title: Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor engineered T cell therapy for solid tumors.

Presenter: Shrikanta Chattopadhyay, M.D.

Abstract Number: 2554

Poster Board Number: 396

Session Title: Developmental Therapeutics – Immunotherapy

Location: Hall A and On Demand

Time: June 3, 2023; 8:00 am – 11:00 am CDT

A copy of the poster will be added to the “Publications” section of the Company’s website at www.tscan.com once the session has concluded.

Total
0
Shares
Related Posts